Cascadian Therapeutics Inc.
14
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
17%
2 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Role: collaborator
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
Role: collaborator
A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
Role: lead
Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers
Role: lead
Phase I Trial of Oral PX-866
Role: lead
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
Role: lead
Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors
Role: lead
Phase I Trial of PX-478
Role: lead
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Role: lead
A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer
Role: lead
Phase 1 and 2 Study of PX-866 and Cetuximab
Role: lead
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Role: lead
Study of PX-866 and Docetaxel in Solid Tumors
Role: lead
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
Role: lead
All 14 trials loaded